How These 2 Healthcare Stocks Performed Amid Pandemic Challenge

Source: BlurryMe, Shutterstock


  • UK's leading cell and gene therapy firm Oxford Biomedica reported a 37 per cent increase in its revenue to £87.7 million for FY20.
  • PureTech’s operating losses shrunk from $135.39 million in 2019 to $119.53 million in 2020.

The healthcare industry remained on the forefront and reacted positively towards the COVID-19 pandemic with powerful technology, virtual healthcare, new innovations and lately with vaccines. The healthcare sector is a space, which is anticipated to see a constant growth due to population growth, among many other factors. There are many healthcare companies that have posted a strong financial result based on their acumen to capitalise on the unprecedented situation.

Let’s take a quick look at two FTSE-listed companies that posted a strong result for the financial year ended in December 2020.

Oxford Biomedica plc


UK's leading cell and gene therapy firm Oxford Biomedica plc (LSE: OXB) released its preliminary financial results for the fiscal year ended December 31, 2020.

The company had a 37 per cent increase in its revenue to £87.7 million. Its new customers, AstraZeneca, Beam Therapeutics, and Juno/BMS, contributed to a 45 per cent rise in bioprocessing and commercial production sales to £68.5 million as compared with the last year's £47.3 million, which is a double-digit increase across all operations.

OXB's licences, milestones & royalties’ revenue also increased to £19.2 million from £16.8 million in 2019 for the same period. It was mainly due to the £7.8 million licence fee from Juno/BMS.

The operating expenses also increased by 23 per cent to £51.7 million in the year, helped by the switch to a lower-cost bioreactor manufacturing process. While its operating net loss shrank from £14.5 million to £5.7 million. The company made an operating EBITDA profit of £7.3 million, up from a loss of £5.2 million the previous year.

Commenting on results, John Dawson, Chief Executive Officer of Oxford Biomedica, said:

Oxford BioMedica's scrip, a constituent of FTSE 250, was trading at GBX 1,048.00, up 0.58 per cent on Friday at the time of writing this article (10:29 AM GMT+1).

PureTech Health Plc

Biotechnology company PureTech Health Plc (LSE: PRTC), which makes medicines to cure serious disease, recorded total revenue of $11.768 million for the FY2020 from $9.807 million in FY2019.

Its operating losses also shrunk from $135.39 million in 2019 to $119.53 million in 2020, mainly due to the cut in administrative and general expenses.

Daphne Zohar, Founder and Chief Executive Officer of PureTech, stated:

FTSE 250-listed PureTech also revealed that profit from its other division has fallen from $672.16 million to $178.73 million, bringing overall full-year pre-tax income to $18.96 million, a significant drop from the previous year's figure of $478.47 million.

Shares of PureTech Health Plc were trading at GBX 412.00, down by 0.60 per cent, at the time of writing this article (11:24 AM GMT+1).

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is not authorised or regulated by the Financial Conduct Authority to provide regulated advice. The purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. The Content is guidance about the different types of investments that are available and sets out general principles to continue before making investment decisions. Kalkine Media is neither authorised nor qualified to provide regulated investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from an appropriately authorised and/or qualified financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.